136 related articles for article (PubMed ID: 32967520)
21. Malignant mesothelioma clinical trial combines immunotherapy drugs.
Chatwal MS; Tanvetyanon T
Immunotherapy; 2018 Apr; 10(5):341-344. PubMed ID: 29473471
[TBL] [Abstract][Full Text] [Related]
22. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.
Spain L; Walls G; Julve M; O'Meara K; Schmid T; Kalaitzaki E; Turajlic S; Gore M; Rees J; Larkin J
Ann Oncol; 2017 Feb; 28(2):377-385. PubMed ID: 28426103
[TBL] [Abstract][Full Text] [Related]
23. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.
Rosner S; Kwong E; Shoushtari AN; Friedman CF; Betof AS; Brady MS; Coit DG; Callahan MK; Wolchok JD; Chapman PB; Panageas KS; Postow MA
Cancer Med; 2018 Mar; 7(3):690-697. PubMed ID: 29468834
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms.
Al-Toubah T; Halfdanarson T; Gile J; Morse B; Sommerer K; Strosberg J
ESMO Open; 2022 Feb; 7(1):100364. PubMed ID: 34973511
[TBL] [Abstract][Full Text] [Related]
25. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
[TBL] [Abstract][Full Text] [Related]
26. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.
Groisberg R; Hong DS; Behrang A; Hess K; Janku F; Piha-Paul S; Naing A; Fu S; Benjamin R; Patel S; Somaiah N; Conley A; Meric-Bernstam F; Subbiah V
J Immunother Cancer; 2017 Dec; 5(1):100. PubMed ID: 29254498
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
[TBL] [Abstract][Full Text] [Related]
28. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
Hsu JC; Lin JY; Hsu MY; Lin PC
PLoS One; 2018; 13(8):e0202725. PubMed ID: 30142174
[TBL] [Abstract][Full Text] [Related]
30. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.
Irwin DE; Davis B; Bell JA; Galaznik A; Garcia-Ribas I
J Comp Eff Res; 2019 Jan; 8(2):81-90. PubMed ID: 30547675
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172).
Schadendorf D; Ascierto PA; Haanen J; Espinosa E; Demidov L; Garbe C; Guida M; Lorigan P; Chiarion-Sileni V; Gogas H; Maio M; Fierro MT; Hoeller C; Terheyden P; Gutzmer R; Guren TK; Bafaloukos D; Rutkowski P; Plummer R; Waterston A; Kaatz M; Mandala M; Marquez-Rodas I; Muñoz-Couselo E; Dummer R; Grigoryeva E; Young TC; Nathan P
Eur J Cancer; 2019 Nov; 121():144-153. PubMed ID: 31581055
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers.
Klein O; Kee D; Markman B; Michael M; Underhill C; Carlino MS; Jackett L; Lum C; Scott C; Nagrial A; Behren A; So JY; Palmer J; Cebon J
Clin Cancer Res; 2020 Sep; 26(17):4454-4459. PubMed ID: 32532787
[TBL] [Abstract][Full Text] [Related]
33. Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy.
Carril-Ajuria L; Lora D; Carretero-González A; Martín-Soberón M; Rioja-Viera P; Castellano D; de Velasco G
Clin Genitourin Cancer; 2021 Apr; 19(2):95-102. PubMed ID: 33189597
[TBL] [Abstract][Full Text] [Related]
34. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
36. Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report.
Iribe Y; Furuya M; Shibata Y; Yasui M; Funahashi M; Ota J; Iwashita H; Nagashima Y; Hasumi H; Hayashi N; Makiyama K; Kondo K; Tanaka R; Yao M; Nakaigawa N
Fam Cancer; 2021 Jan; 20(1):75-80. PubMed ID: 32666341
[TBL] [Abstract][Full Text] [Related]
37. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
[TBL] [Abstract][Full Text] [Related]
38. Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma.
Mason R; Dearden HC; Nguyen B; Soon JA; Smith JL; Randhawa M; Mant A; Warburton L; Lo S; Meniawy T; Guminski A; Parente P; Ali S; Haydon A; Long GV; Carlino MS; Millward M; Atkinson VG; Menzies AM
Pigment Cell Melanoma Res; 2020 Mar; 33(2):358-365. PubMed ID: 31587511
[TBL] [Abstract][Full Text] [Related]
39. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort.
Patel SP; Mayerson E; Chae YK; Strosberg J; Wang J; Konda B; Hayward J; McLeod CM; Chen HX; Sharon E; Othus M; Ryan CW; Plets M; Blanke CD; Kurzrock R
Cancer; 2021 Sep; 127(17):3194-3201. PubMed ID: 33882143
[TBL] [Abstract][Full Text] [Related]
40. Ipilimumab and nivolumab: the 'new kid on the block' in advanced angiosarcoma.
Assi T; Ibrahim R; Ibrahim T; Khoury R; Cesne AL
Immunotherapy; 2023 Oct; 15(14):1089-1091. PubMed ID: 37585663
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]